The core of the global bio industry remains in Boston and South San Francisco, but emerging bio clusters in Beijing, London and Seattle are rapidly expanding their influence. Since COVID‑19, nations have promoted biotech as a strategic industry, leading to a multipolar shift in global bio hubs. According to CBRE’s Global Life Sciences Atlas, laboratory and R&D space under construction worldwide last year surpassed 35 million square feet (about 3.25 million m²).
Analyse3 sept. 2026•1 min de lecture
Emerging Bio Clusters Expand as Global R&D Space Tops 35M Sq Ft
CBRE reports worldwide biotech R&D construction exceeds 35 million sq ft, as new clusters in Beijing, London and Seattle grow alongside Boston and San Francisco.
Compilé par l'équipe PharmaCountry · Source : KPA News
Évaluations
(0)
(0)
(0)
(0)
(0)
Plus d'articles
Voir tous les articlesRecherches & Rapports
Global Finished Dosage Manufacturing Landscape 2026
5 oct. 2026
Actualités réglementairesKorea Korus hit with 1‑month manufacturing suspension over missing post‑marketing safety test
28 sept. 2026
AnalysePharma distributors set delivery cut‑offs ahead of Chuseok holiday (Sep 21‑23)
28 sept. 2026
Laissez votre note